Abstract：Objective To investigate the clinical efficacy of Xiaoer Jingxing Zhike granules combined with recombinant human interferon α1b in the treatment of infantile bronchiolitis. Methods    A total of 118 children with capillary bronchitis infants admitted to our hospital from March 2020 to June 2021 were divided into Chinese and Western group and the control group accordance with the treatment method, each group of 59 cases. The patients in the control group were treated with human recombinant interferon α1b atomization inhalation, and in Chinese and Western group were combined with Xiaoer Jingxing Zhike granules on the basis of the control group. Clinical efficacy, symptom regression time, blood gas analysis results before and after treatment, inflammatory factors, immune function and adverse reactions were compared between the two groups. Results The total effective rate of Chinese and Western groups was significantly higher than that of control group and the difference was statistically significant（χ2＝7.002, P＜0.05）. The clinical symptoms of shortness of breath, wheezing, cough, lung rales and wheezing disappeared in the Chinese and Western groups were significantly shorter than those in the control group, PaO2, PaCO2, CRP, IL-6, TNF-α, IgA, IgG and IgM in Chinese and Western groups were significantly better than those in control group after treatment. The difference between the groups were statistically significant（t＝5.291, 4.432, 6.575, 4.824, 5.115, 9.562, 12.363, 11.514, 6.251, 4.627, 9.235, 6.674, 5.378，all P＜0.05）. The difference of the incidence of adverse reactions compared between the two groups was no statistically significant（χ2＝0.100, P＞0.05）. Conclusion Xiaoer Jingxing Zhike granules combined with recombinant human interferon α1b in the treatment of pediatric bronchiolitis can improve the therapeutic effect and alleviate the disease, improve lung function, control inflammatory response, improve immune status, and high safety.